当前位置: X-MOL 学术Drug. Discov. Today › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Cell-based immunomodulatory therapy approaches for type 1 diabetes mellitus.
Drug Discovery Today ( IF 7.4 ) Pub Date : 2019-12-12 , DOI: 10.1016/j.drudis.2019.11.016
Labe Black 1 , Tatiana Zorina 1
Affiliation  

Physiologically sufficient β cell regeneration can be achieved by the induction of hematopoietic chimerism in a type 1 diabetes mellitus (T1DM) mouse model. However, pancytopenia and graft-versus-host disease (GVHD) limits the clinical adaptation of this modality. In this review, we discuss new perceptions on the induction of chimerism, without bone marrow (BM) recipient conditioning, via supplementation of mesenchymal stem cells (MSCs) to support engraftment of allogeneic HSCs. The use of haploidentical, gender-matched, predisposing T1DM genotype-free HSCs in combination with MHC-disparate MSCs could lead to the development of a safe protocol for the induction of hematopoietic chimerism for the treatment of T1DM.

中文翻译:

1型糖尿病的基于细胞的免疫调节治疗方法。

在1型糖尿病(T1DM)小鼠模型中,通过诱导造血嵌合体可以实现生理上足够的β细胞再生。但是,全血细胞减少症和移植物抗宿主病(GVHD)限制了这种方式的临床适应性。在这篇综述中,我们讨论了在没有骨髓(BM)受体调节的情况下,通过补充间充质干细胞(MSC)支持同种异体HSC的植入对嵌合体诱导的新认识。与MHC不同的MSC结合使用单倍性,性别匹配,易患T1DM的无基因型HSC可能会导致开发用于诱导造血嵌合体治疗T1DM的安全方案。
更新日期:2019-12-13
down
wechat
bug